Hepatitis C virus–kidney transplantation relationship

The Hepatitis C virus–kidney transplantation relationship links a systemic viral infection to the survival, eligibility, timing, and long-term outcomes of kidney transplant candidates and recipients. HCV is not confined to the liver: it can produce renal and immune-mediated disease, while chronic infection increases mortality in patients with end-stage renal disease and may progress more rapidly when immunosuppression follows kidney transplantation. The relationship therefore becomes a chain of clinical decisions—screening, confirmation of active infection, liver staging, treatment before transplantation, surveillance on the waiting list, and selection of an appropriate transplant strategy.

Definition and Clinical Stakes

HCV infection is especially consequential in end-stage renal disease because it affects both the period of dialysis and the period after transplantation. Chronic infection develops in around 80% of people after acute infection, and approximately 20% of adults with chronic HCV infection are expected to develop cirrhosis about 20 years after infection. Among dialysis patients, a meta-analysis of 11,589 individuals from seven observational studies found a relative risk of mortality of 1.34 for HCV-positive patients, while the relative risk of death from liver disease was 5.89. These figures make HCV more than a coincidental laboratory finding in a transplant candidate: it is a factor that can alter life expectancy before and after a graft is received.

The infection also has a specifically transplant-related biological consequence. Immunosuppressive therapy after kidney transplantation induces increased viral replication; in the reported experience, viremia rose immediately after transplantation and reached a peak between six and twelve months. The extent of liver injury varies with gender, HCV genotype, duration of infection, coinfection with other hepatotropic viruses, and potentially hepatotoxic drugs used after transplantation. In a comparison of otherwise homogeneous groups, serum HCV RNA correlated positively with hepatic inflammation. Another biopsy study found histological damage in 70% of HCV-positive kidney transplant recipients compared with 19% of HCV-positive controls, and progression to cirrhosis at a second biopsy occurred in 21% of the transplant group compared with 3.6% of controls.

Screening and Liver Assessment

The relationship is first organized through classification. A transplant evaluation should identify anti-HCV antibodies and, where appropriate, active viremia by nucleic acid testing. In low-prevalence regions, screening may begin with an enzyme-linked immunoassay and confirmation of positive results by nucleic acid testing; in high-prevalence settings, direct nucleic acid testing is appropriate. This distinction matters because antibody positivity does not by itself establish current viral replication, whereas detectable HCV RNA identifies active infection requiring further assessment.

Patients with active HCV infection require evaluation of both hepatic and extrahepatic disease. Studies cited in the transplant literature found advanced liver injury—stage 3 or 4 disease, including cirrhosis—in 10–25% of kidney transplant candidates when biopsies were performed during pretransplant evaluation. Noninvasive markers have been sought, but the available evidence still places liver biopsy as the gold standard for determining the extent of liver damage. The KDIGO workgroup recommended percutaneous liver biopsy for all HCV-infected patients being considered for kidney transplantation, despite continuing interest in less invasive methods.

The result of this staging determines whether kidney-alone transplantation is suitable. Patients with established or decompensated cirrhosis should be referred to a liver transplant team for consideration of simultaneous liver–kidney transplantation rather than treated as ordinary kidney-alone candidates. The relationship thus converts liver histology into a question of organ allocation and transplant architecture: the same viral infection can lead one patient toward kidney transplantation and another toward a combined procedure.

Treatment Before Transplantation

Antiviral therapy is generally more valuable before kidney transplantation than after it. In dialysis patients, conventional interferon or reduced-dose pegylated interferon may be considered, with treatment individualized according to likely benefit, treatment risk, life expectancy, the possibility of receiving a kidney, and comorbidities. KDIGO recommendations described 48 weeks of therapy for genotype 1 or 4 when an appropriate early viral decline occurred, and 24 weeks for genotype 2 or 3. Ribavirin was not routinely recommended for patients on dialysis, although it could be combined with low-dose interferon under strict monitoring for anemia.

The rationale for pretransplant treatment has several parts. HCV is associated with increased overall and liver-related mortality on dialysis; liver disease may progress more quickly after transplantation; and interferon given after transplantation increases the risk of renal allograft rejection and graft loss. For these reasons, guidelines recommended antiviral treatment for all HCV-positive kidney transplant candidates, while still requiring individualized assessment. Achieving a sustained virological response before transplantation may also reduce the later risk of posttransplant diabetes and immune complex-mediated glomerular disease in the allograft, although the evidence for an effect on long-term liver-injury progression remains limited.

Treatment is constrained by toxicity and feasibility. Interferon-based therapy can produce influenza-like symptoms, fatigue, headache, muscle and joint pain, anemia, neutropenia, depression, and anxiety. Across treatment populations, toxicity led to dose reduction in 35–42% of patients and discontinuation in about 30%. Therapy may also be prolonged, expensive, and unavailable to some patients. A patient may decline treatment, fail to respond, withdraw, or be unable to tolerate it; excluding such a patient from transplantation indefinitely may be more harmful than proceeding. The evidence therefore presents treatment not as a universal gateway to transplantation but as a decision whose risks must be weighed against the consequences of remaining on dialysis.

Waiting-List Surveillance and Eligibility

HCV status continues to matter after listing. Because deceased-donor waiting times in some parts of the United States approach five to seven years, a transplant center needs an ongoing surveillance protocol rather than a single screening result. A patient with active HCV RNA should be placed on hold status and referred to a hepatologist for evaluation and possible treatment. A patient who has achieved a sustained virological response should undergo nucleic acid testing at least annually to confirm that the response remains durable; relapse requires renewed referral and consideration of retreatment.

Patients who remain viremic while waiting require regular assessment for progression of liver disease. In one group of 13 candidates who underwent repeat biopsy during the waiting period, 8, or 62%, showed interval worsening of liver histology. By contrast, among posttransplant follow-up biopsies, only 7 of 31, or 23%, showed interval worsening. The contrast does not erase the risks of transplantation, but it demonstrates why prolonged dialysis and waiting cannot be treated as a neutral holding pattern. Suggested biopsy intervals were five years for Metavir stage 1 or 2 fibrosis and three years for stage 3 fibrosis. Progression to early or established cirrhosis should lead to removal from the kidney-only list and referral for consideration of simultaneous liver–kidney transplantation.

HCV-Positive Donors and Transplant Policy

HCV also shapes the supply side of kidney transplantation. Because HCV can be transmitted through organ transplantation, kidneys from HCV-positive donors have traditionally been classified as nonstandard-risk organs. Their use remains controversial, and practice varies widely: many centers refuse them, while some countries impose technical or legal restrictions. Yet the shortage of donated kidneys creates a competing danger. Patients may deteriorate or die while waiting, and organs that could shorten the waiting period may be discarded.

For selected HCV-positive recipients who are not candidates for, refuse, fail, or cannot afford interferon-based treatment, transplantation with an HCV-positive kidney may offer a more favorable course than continued dialysis. The proposed advantage is a shorter waiting time, especially when the recipient already has active HCV RNA and is unlikely to receive interferon after transplantation. This approach is not compatible with a policy that requires viral eradication before transplantation, but the limitations of antiviral treatment make such a policy impossible for every patient.

The mismatch between donor availability and institutional acceptance has measurable consequences. Donated HCV-positive kidneys were reported to be 2.60 times more likely to be discarded than HCV-negative kidneys. Organizational strategies could therefore redirect these organs to appropriate recipients when they are not used locally, including preemptive transplantation into HCV-positive recipients who will not undergo interferon therapy. The policy question is not simply whether an infected organ is risk-free—it is not—but whether discarding it imposes a greater danger than accepting a carefully assessed transplant and reducing time exposed to dialysis.

Broader Consequences for Patients

The relationship is experienced not only through liver biopsies, viral loads, and graft outcomes but also through the burdens of dialysis and treatment. HCV-related liver disease is often asymptomatic in long-term dialysis, and fatigue, cognitive impairment, and other symptoms may be attributed to dialysis itself because they occur regardless of serologic status. Nevertheless, HCV-positive dialysis patients have shown biochemical differences, including altered liver enzymes and higher intact parathormone levels, while cirrhosis remains relatively infrequent in Western dialysis registries, at about 1.5–2%.

Quality of life adds another layer to transplant decision-making. In a study of 165 regular dialysis patients, 83 of whom were anti-HCV positive, anti-HCV positivity was independently associated with a lower mental component score on the SF-36 questionnaire, although no association with the physical component score was found. Depression may reflect the diagnosis itself, concern about long-term health, fatigue, or cognitive impairment, and dialysis independently contributes to depressive symptoms. Thus, even where liver disease appears clinically quiet, HCV may still shape the patient’s mental experience of illness and the perceived value of treatment or transplantation.

The overall relationship is consequently both biological and institutional. HCV can replicate more intensely under immunosuppression, accelerate posttransplant liver injury, and contribute to renal and immune-complex complications; interferon can threaten the renal allograft; active viremia can place a candidate on hold; biopsy results can redirect a patient toward combined transplantation; and donor serology can determine whether a kidney is discarded or used. The central clinical task is to keep these distinctions visible while making a timely decision: neither HCV positivity nor transplantation alone defines the outcome, but their interaction determines which risks a patient must face and which opportunities remain available.